Criocore provides an automated 3D bioprinting platform that creates human tissue constructs for preclinical drug efficacy and toxicity testing. The scalable, physiologically relevant models integrate with standard assay formats, enabling pharmaceutical and biotech firms to replace animal studies with high‑throughput, human‑relevant data.
Funding
Funding not disclosed
Founders
Product
Problem
Drug discovery and toxicology testing rely heavily on animal studies and low‑throughput cell assays, which often fail to predict human responses accurately and slow candidate screening.
Solution
Criocore offers a bioprinting platform that manufactures human tissue constructs for preclinical testing. By using automated 3D bioprinting, the system produces scalable, physiologically relevant tissue models that mimic native organ architecture and function. These tissue analogs can be integrated into existing drug screening workflows, enabling more reliable assessment of efficacy and toxicity. The approach reduces dependence on animal experiments, shortens development timelines, and improves the translational predictability of candidate compounds.
Target Audience
Primary customers are pharmaceutical and biotech companies seeking reliable preclinical models for drug efficacy and safety testing, as well as contract research organizations that provide toxicology services.
Features
- Automated 3D bioprinting of human tissue constructs with controlled cell composition and spatial organization
- Scalable production pipelines that generate consistent tissue models for high‑throughput screening
- Validated tissue analogs that replicate key physiological and biochemical properties of target organs
- Compatibility with standard assay formats and integration into existing drug discovery workflows
- Data on human-relevant pharmacokinetic and toxicological responses to enhance predictive accuracy